Mani Foroohar
Stock Analyst at Leerink Partners
(2.15)
# 2,607
Out of 4,827 analysts
173
Total ratings
45.74%
Success rate
-9.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LXEO Lexeo Therapeutics | Maintains: Outperform | $19 → $18 | $2.83 | +536.04% | 3 | Mar 24, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $4.41 | +36.05% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $3.03 | +791.09% | 9 | Jan 13, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $46 → $44 | $7.02 | +526.78% | 10 | Nov 19, 2024 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $14.66 | +391.30% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $2.09 | +713.40% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $45.47 | +7.78% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $34.54 | +33.18% | 15 | Oct 17, 2024 | |
| WVE Wave Life Sciences | Maintains: Outperform | $20 → $22 | $6.51 | +237.94% | 6 | Oct 16, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $53 → $62 | $32.71 | +89.54% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $13.81 | -5.87% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $23.68 | +22.47% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $230 | $36.78 | +525.34% | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $3.52 | +13.64% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $7.47 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $3.02 | +926.49% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.41 | +1,623.71% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $13.02 | +207.22% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $111 → $93 | $24.72 | +276.21% | 17 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $8.19 | +925.64% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $1.46 | +379.45% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $180 → $160 | $3.61 | +4,332.13% | 10 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $17.75 | +333.80% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $251.74 | -43.20% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $5.35 | +12.15% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $35.95 | +111.40% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $0.78 | +4,232.31% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $2.91 | +587.29% | 6 | Jul 23, 2021 |
Lexeo Therapeutics
Mar 24, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $2.83
Upside: +536.04%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $4.41
Upside: +36.05%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $3.03
Upside: +791.09%
Rocket Pharmaceuticals
Nov 19, 2024
Maintains: Outperform
Price Target: $46 → $44
Current: $7.02
Upside: +526.78%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $14.66
Upside: +391.30%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $2.09
Upside: +713.40%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $45.47
Upside: +7.78%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $34.54
Upside: +33.18%
Wave Life Sciences
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $6.51
Upside: +237.94%
Ionis Pharmaceuticals
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $32.71
Upside: +89.54%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $13.81
Upside: -5.87%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $23.68
Upside: +22.47%
Jun 24, 2024
Maintains: Outperform
Price Target: $165 → $230
Current: $36.78
Upside: +525.34%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $3.52
Upside: +13.64%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $7.47
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $3.02
Upside: +926.49%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.41
Upside: +1,623.71%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $13.02
Upside: +207.22%
Feb 24, 2023
Downgrades: Underperform
Price Target: $111 → $93
Current: $24.72
Upside: +276.21%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $8.19
Upside: +925.64%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $1.46
Upside: +379.45%
Jan 23, 2023
Maintains: Market Perform
Price Target: $180 → $160
Current: $3.61
Upside: +4,332.13%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $17.75
Upside: +333.80%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $251.74
Upside: -43.20%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $5.35
Upside: +12.15%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $35.95
Upside: +111.40%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $0.78
Upside: +4,232.31%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $2.91
Upside: +587.29%